EcoDrugPlus

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSPKIG00000024716
Gene Symbol: UGCG
3 Cross references
211 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSPKIG00000016550
Gene Symbol: WEE1
4 Cross references
148 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSPKIG00000000105
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSPKIG00000014125
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSPKIG00000002363
Gene Symbol: LOC111850174
3 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSPKIG00000024204
Gene Symbol: ADORA1
3 Cross references
248 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSPKIG00000006560
Gene Symbol: ADORA2A
3 Cross references
258 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSPKIG00000015453
Gene Symbol: ADORA2A
3 Cross references
258 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSPKIG00000019530
Gene Symbol: ADORA2B
3 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSPKIG00000011595
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSPKIG00000011607
Gene Symbol: LOC111855247
2 Cross references
4 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSPKIG00000001010
Gene Symbol: LOC111837006
3 Cross references
152 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).